Special Issue

Von Hippel-Lindau and Cancers

Message from the Guest Editors

Von Hippel–Lindau disease (VHL) is a rare and inheritable tumor syndrome with an autosomal dominant pattern that affects multiple organs. The disease was named after the German ophthalmologist, Eugen von Hippel, who first described ophthalmic angiomas in 1904, and the Swedish pathologist, Arvid Lindau, who discovered "angiomatosis of the central nervous system" in 1927. VHL disease is caused by germline alterations in the VHL gene. The importance of this pathway was highlighted in 2019 as three investigators who discovered the cellular response to hypoxia received the Nobel Prize in Physiology or Medicine. In this Special Issue, we include a brief history of VHL; the detailed molecular pathophysiology of VHL-HIF and tumorigenesis; organ-specific phenotypes such as retinal, brain, and spine hemangioblastomas; pheochromocytoma and paragangliomas; pancreatic cysts and neuroendocrine tumors; and urologic manifestations of VHL with a focus on renal cell cancer. The updated surgical and medical management and surveillance programs are also discussed. For further reading, please, visit the Special Issue website.

Guest Editors

Dr. Naris Nilubol

Endocrine Surgery Section, Surgical Oncology Program, National Cancer Institute, NIH, Bethesda, MD 20892, USA

Dr. Mark W. Ball

Center for Cancer Research National Cancer Institute, NIH, Bethesda, MD 20892, USA

Deadline for manuscript submissions

closed (15 November 2023)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/111186

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)